Clinton Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Clinton Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,891	Closed	-$322K	–	513
2018 Q1	$322K	Buy	+2,891	New	+$346K	0.03%	302
2017 Q4	–	Sell	-1,812	Closed	-$254K	–	538
2017 Q3	$254K	Buy	+1,812	New	+$246K	0.03%	340
2016 Q4	–	Sell	-10,818	Closed	-$1.33M	–	1066
2016 Q3	$1.33M	Sell	10,818 -50,861	-82%	-$6.55M	0.06%	388
2016 Q2	$7.2M	Buy	+61,679	New	+$8.75M	0.32%	84
2015 Q2	–	Sell	-9,459	Closed	-$1.64M	–	740
2015 Q1	$1.64M	Buy	+9,459	New	+$1.71M	0.43%	57
2014 Q3	–	Sell	-8,977	Closed	-$1.4M	–	509
2014 Q2	$1.4M	Buy	8,977 +5,072	+130%	+$801K	0.7%	24
2014 Q1	$594K	Buy	+3,905	New	+$621K	0.22%	142

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Clinton Group's ALXN Position: Q2 2018 in Review

Clinton Group sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 2,891 shares — an estimated $322K sold.

Clinton Group first reported a position in ALXN in Q1 2014 and held it in 7 quarters. The position peaked at $7.2M in Q2 2016. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

Clinton Group reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Clinton Group sold 2,891 Alexion Pharmaceuticals shares in Q2 2018, an estimated $322K.
Clinton Group first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Clinton Group's Alexion Pharmaceuticals position peaked at $7.2M in Q2 2016.
601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Clinton Group's 13F filing for Q2 2018, filed 6 Jul 2018.